Know Cancer

or
forgot password

Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Metastatic Melanoma

Thank you

Trial Information

Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients


Inclusion Criteria:



- Metastatic Melanoma patients failing to prior chemo and immunotherapy with good
performance status.

Exclusion Criteria:

- Brain mets

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate and toxicity

Outcome Time Frame:

6 months

Safety Issue:

Yes

Principal Investigator

Jacob Schachter, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Head, Ella Institute, Sheba Medical Center

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

SHEBA-04-3518-JS-CTIL

NCT ID:

NCT00287131

Start Date:

January 2006

Completion Date:

November 2013

Related Keywords:

  • Metastatic Melanoma
  • melanoma
  • metastatic melanoma
  • adoptive immunotherapy
  • IL-2
  • Melanoma

Name

Location